Mizuho cuts Articus to neutral, cites lower-than-expected prescriptions (NASDAQ:ARQT)


Psoriasis Blue Marker

IvelinRadkov/iStock via Getty Images

Mizuho cut its rating of Arcutis Biotherapeutics (NASDAQ:ARQT) to neutral and slashed its price target, citing lower than expected prescriptions for the drug roflumilast.

The investment bank said it had been bullish on the stock because it believed the market

Source link

Leave A Reply

Your email address will not be published.